

Eric Jonasch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7632919/publications.pdf>

Version: 2024-02-01

221
papers

12,753
citations

20759

60
h-index

30848

102
g-index

226
all docs

226
docs citations

226
times ranked

13894
citing authors

#	ARTICLE	IF	CITATIONS
1	Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. <i>BJU International</i> , 2022, 129, 610-620.	1.3	22
2	Gene Body Methylation of the Lymphocyte-Specific Gene <i>CARD11</i> Results in Its Overexpression and Regulates Cancer mTOR Signaling. <i>Molecular Cancer Research</i> , 2022, 19, 1917-1928.	1.5	3
3	Sunitinib-Related Osteonecrosis of the External Auditory Canal: Case Report. <i>Otolaryngology - Head and Neck Surgery</i> , 2022, 167, 607-608.	1.1	3
4	Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?. <i>Cancers</i> , 2022, 14, 644.	1.7	11
5	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 71-90.	2.3	248
6	Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries. <i>European Urology Open Science</i> , 2022, 37, 3-6.	0.2	4
7	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	3.2	12
8	A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. <i>Science Translational Medicine</i> , 2022, 14, eabm6420.	5.8	29
9	VHL-P138R and VHL-L163R Novel Variants: Mechanisms of VHL Pathogenicity Involving HIF-Dependent and HIF-Independent Actions. <i>Frontiers in Endocrinology</i> , 2022, 13, 854365.	1.5	0
10	Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 808-824.	1.8	2
11	Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. <i>World Journal of Urology</i> , 2021, 39, 2409-2415.	1.2	28
12	Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. <i>Nature Reviews Nephrology</i> , 2021, 17, 245-261.	4.1	278
13	Maternal and fetal outcomes in pheochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 13-21.	5.5	37
14	Phase II study of the oral hypoxia-inducible factor 2 \pm (HIF-2 \pm) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 333-333.	0.8	3
15	Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2265.	1.8	12
16	The oral HIF-2 \pm inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 273-273.	0.8	19
17	Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1475.	1.7	10
18	Combination antiangiogenic tyrosine kinase inhibition and anti- PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. <i>Cancer Medicine</i> , 2021, 10, 2341-2349.	1.3	15

#	ARTICLE	IF	CITATIONS
19	Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. <i>Oncologist</i> , 2021, 26, 476-482.	1.9	19
20	Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. <i>Cancers</i> , 2021, 13, 2170.	1.7	15
21	Inhibition of hypoxia-inducible factor-2 β in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. <i>Nature Medicine</i> , 2021, 27, 802-805.	15.2	151
22	MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 495-504.	1.9	24
23	Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. <i>Cell</i> , 2021, 184, 2988-3005.e16.	13.5	166
24	Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 790.e17-790.e23.	0.8	3
25	Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. , 2021, 9, e002850.		15
26	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. <i>Cancer</i> , 2021, 127, 3957-3966.	2.0	11
27	Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 837.e9-837.e17.	0.8	3
28	Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermuted cancers. <i>Science Translational Medicine</i> , 2021, 13, eabe6201.	5.8	19
29	Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1732-1739.	5.1	84
30	Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 6375.	5.8	22
31	Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. <i>New England Journal of Medicine</i> , 2021, 385, 2036-2046.	13.9	274
32	Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. <i>Cancer Treatment Reviews</i> , 2020, 89, 102062.	3.4	14
33	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. <i>ESMO Open</i> , 2020, 5, e001073.	2.0	1
34	PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. <i>Nature Communications</i> , 2020, 11, 2135.	5.8	114
35	Chronic hepatitis C virus infection and genitourinary cancers: A case-control study. <i>Seminars in Oncology</i> , 2020, 47, 165-167.	0.8	0
36	Macrophage HIF-1 β Is an Independent Prognostic Indicator in Kidney Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4970-4982.	3.2	45

#	ARTICLE	IF	CITATIONS
37	Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. <i>British Journal of Cancer</i> , 2020, 123, 898-904.	2.9	36
38	Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. <i>Cancer Cell</i> , 2020, 37, 371-386.e12.	7.7	68
39	Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. <i>Oncologist</i> , 2020, 25, 252-258.	1.9	62
40	Phase II study of the oral HIF-2 α inhibitor MK-6482 for Von Hippel-Lindau disease-associated renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5003-5003.	0.8	40
41	Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 611-611.	0.8	33
42	Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. <i>JCO Oncology Practice</i> , 2020, 16, e1264-e1271.	1.4	16
43	NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1160-1170.	2.3	163
44	SET-ing the stage for PI3K β inhibitor sensitivity in clear cell renal cell carcinoma. <i>Oncotarget</i> , 2019, 10, 1540-1541.	0.8	0
45	MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma. <i>Oncogene</i> , 2019, 38, 6211-6225.	2.6	78
46	Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 451-456.	0.9	7
47	Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras α -ERK Pathway Activation in Hypoxia. <i>Molecular Cancer Research</i> , 2019, 17, 1220-1232.	1.5	22
48	Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e526-e533.	0.9	9
49	Durable complete response in renal cell carcinoma clinical trials. <i>Lancet, The</i> , 2019, 393, 2362-2364.	6.3	7
50	SETD2 regulates the maternal epigenome, genomic imprinting and embryonic development. <i>Nature Genetics</i> , 2019, 51, 844-856.	9.4	207
51	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019, 24, 491-497.	1.9	22
52	Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. <i>Nature Metabolism</i> , 2019, 1, 431-444.	5.1	158
53	Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 11.	1.3	11
54	Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. <i>Communications Biology</i> , 2019, 2, 386.	2.0	81

#	ARTICLE	IF	CITATIONS
55	A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx).. Journal of Clinical Oncology, 2019, 37, 4501-4501.	0.8	9
56	An open-label phase II study to evaluate PT2977 for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, TPS680-TPS680.	0.8	7
57	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1278-1285.	2.3	185
58	Renal cell carcinoma brain metastasis with pseudoprogression and radiation necrosis on nivolumab after previous treatment with stereotactic radiosurgery: An illustrative case report and review of the literature. Practical Radiation Oncology, 2018, 8, e262-e265.	1.1	8
59	Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma. Palliative and Supportive Care, 2018, 16, 146-154.	0.6	5
60	Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, e47-e57.	0.9	12
61	BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia, 2018, 20, 32-43.	2.3	13
62	Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2018, 36, 1588-1593.	0.8	39
63	Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncology, The, 2018, 19, 1351-1359.	5.1	63
64	Updates to the Management of Kidney Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 639-641.	2.3	29
65	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science, 2018, 361, 290-295.	6.0	134
66	AKT isoform-specific expression and activation across cancer lineages. BMC Cancer, 2018, 18, 742.	1.1	32
67	Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 783-793.	1.6	42
68	A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, 2508-2508.	0.8	21
69	Homologous repair deficiency in VHL-mutated clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 585-585.	0.8	3
70	Pilot study of dovitinib in patients with von Hippel-Lindau disease. Oncotarget, 2018, 9, 23390-23395.	0.8	15
71	Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support. Psycho-Oncology, 2017, 26, 1361-1368.	1.0	22
72	Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clinical Genitourinary Cancer, 2017, 15, 363-370.	0.9	17

#	ARTICLE	IF	CITATIONS
73	Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. <i>Journal of Urology</i> , 2017, 198, 530-537.	0.2	55
74	Incorporating New Systemic Therapies in Kidney Cancer Treatment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 703-705.	2.3	4
75	Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2017, 12, 333-340.	1.7	5
76	Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. <i>BJU International</i> , 2017, 120, 782-792.	1.3	68
77	Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. <i>Cancer</i> , 2017, 123, 4823-4831.	2.0	79
78	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 804-834.	2.3	443
79	Recommendations for the Management of Rare Kidney Cancers. <i>European Urology</i> , 2017, 72, 974-983.	0.9	36
80	Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. <i>Clinical Cancer Research</i> , 2017, 23, 6686-6696.	3.2	66
81	HNFB Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. <i>Cancer Research</i> , 2017, 77, 5313-5326.	0.4	19
82	Outcomes of Patients With Metastatic Non-clear-Cell Renal Cell Carcinoma Treated With Pazopanib. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e205-e208.	0.9	24
83	Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening. <i>BMC Genomics</i> , 2017, 18, 678.	1.2	24
84	Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2017, 1, 57-64.	0.2	8
85	Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2993-3001.	0.8	145
86	Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 42149-42158.	0.8	6
87	Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. <i>BJU International</i> , 2016, 117, 761-765.	1.3	56
88	NCCN Evidence Blocks. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 616-619.	2.3	44
89	Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 537-549.	12.5	72
90	Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 499-503.	0.9	39

#	ARTICLE	IF	CITATIONS
91	The use of spine stereotactic radiosurgery for oligometastatic disease. <i>Journal of Neurosurgery: Spine</i> , 2016, 25, 239-247.	0.9	43
92	Key considerations in the treatment of von Hippel-Lindau disease. <i>Future Oncology</i> , 2016, 12, 1755-1758.	1.1	3
93	The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. <i>Journal of Urology</i> , 2016, 196, 678-684.	0.2	24
94	Treatment of Relapsed Germ Cell Tumors: Time For Something New?. <i>Journal of Oncology Practice</i> , 2016, 12, 449-450.	2.5	1
95	Dual Chromatin and Cytoskeletal Remodeling by SETD2. <i>Cell</i> , 2016, 166, 950-962.	13.5	204
96	Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a sin. <i>BJU International</i> , 2016, 118, 264-271.	1.3	17
97	Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. <i>Current Medical Research and Opinion</i> , 2016, 32, 741-747.	0.9	12
98	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. <i>European Urology</i> , 2016, 69, 866-874.	0.9	272
99	Autophagy degrades hypoxia inducible factors. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1104428.	0.3	12
100	Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. <i>European Urology</i> , 2016, 70, 348-357.	0.9	111
101	Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. <i>Journal of Medical Economics</i> , 2016, 19, 462-468.	1.0	7
102	Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 237.e19-237.e26.	0.8	13
103	The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. <i>European Radiology</i> , 2016, 26, 2798-2807.	2.3	33
104	Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. <i>Modern Pathology</i> , 2016, 29, 34-42.	2.9	55
105	Fast clearance of lipid droplets through MAP1S-activated autophagy suppresses clear cell renal cell carcinomas and promotes patient survival. <i>Oncotarget</i> , 2016, 7, 6255-6265.	0.8	40
106	Kidney Cancer, Version 3.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 151-159.	2.3	198
107	Testicular Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 772-799.	2.3	98
108	Kidney Cancer: Current and Novel Treatment Options. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 679-681.	2.3	0

#	ARTICLE	IF	CITATIONS
109	Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 427.e17-427.e23.	0.8	35
110	The impact of FGFR1 and FRS2 \pm expression on sorafenib treatment in metastatic renal cell carcinoma. <i>BMC Cancer</i> , 2015, 15, 304.	1.1	16
111	Dysregulation of HIF2 \pm and autophagy in renal cell carcinoma. <i>Molecular and Cellular Oncology</i> , 2015, 2, e965643.	0.3	3
112	Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 212-224.	1.3	12
113	Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress screening. <i>Psycho-Oncology</i> , 2015, 24, 1477-1484.	1.0	23
114	Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2015, 3, 1017-1029.	1.6	159
115	Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. <i>Modern Pathology</i> , 2015, 28, 1225-1235.	2.9	23
116	Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2015, 26, 1300-1304.	0.6	39
117	Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 166.e21-166.e29.	0.8	44
118	The PI3K/AKT Pathway and Renal Cell Carcinoma. <i>Journal of Genetics and Genomics</i> , 2015, 42, 343-353.	1.7	267
119	Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. <i>Journal of Urology</i> , 2015, 194, 316-322.	0.2	49
120	Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 805-819.	0.9	7
121	First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 210-217.	0.9	23
122	Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial. <i>Oncologist</i> , 2015, 20, 1140-1148.	1.9	13
123	The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell Carcinoma. <i>Radiology</i> , 2015, 277, 114-123.	3.6	61
124	Hypoxia-Induced SUMOylation of E3 Ligase HAF Determines Specific Activation of HIF2 in Clear-Cell Renal Cell Carcinoma. <i>Cancer Research</i> , 2015, 75, 316-329.	0.4	34
125	Psychological states, serum markers and survival: associations and predictors of survival in patients with renal cell carcinoma. <i>Journal of Behavioral Medicine</i> , 2015, 38, 48-56.	1.1	15
126	Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices. <i>Current Medical Research and Opinion</i> , 2014, 30, 2041-2050.	0.9	37

#	ARTICLE	IF	CITATIONS
127	Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. <i>Current Medical Research and Opinion</i> , 2014, 30, 2343-2353.	0.9	13
128	Mammalian target of rapamycin (<sc>mTOR</sc>) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. <i>BJU International</i> , 2014, 113, 376-382.	1.3	48
129	Axitinib for the Treatment of Metastatic Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 397-403.	0.6	23
130	Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules. <i>Journal of Urology</i> , 2014, 191, 611-618.	0.2	122
131	Outcomes of Patients With Metastatic Renal Cell Carcinoma and End-Stage Renal Disease Receiving Dialysis and Targeted Therapies: A Single Institution Experience. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 348-353.	0.9	36
132	Partial Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 36-42.	0.2	12
133	Genetic and Pharmacological Strategies to Refunctionalize the von Hippel Lindau R167Q Mutant Protein. <i>Cancer Research</i> , 2014, 74, 3127-3136.	0.4	20
134	Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. <i>Genome Research</i> , 2014, 24, 241-250.	2.4	160
135	Renal cell carcinoma. <i>BMJ, The</i> , 2014, 349, g4797-g4797.	3.0	509
136	Clear cell papillary renal cell carcinoma in patients with von Hippel-Lindau syndrome—clinicopathological features and comparative genomic analysis of 3 cases. <i>Human Pathology</i> , 2014, 45, 1966-1972.	1.1	31
137	Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. <i>Cancer</i> , 2014, 120, 1794-1799.	2.0	154
138	Genetic Kidney Cancer Syndromes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1347-1355.	2.3	26
139	Kidney Cancer, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 175-182.	2.3	56
140	Cadherin-11 in Renal Cell Carcinoma Bone Metastasis. <i>PLoS ONE</i> , 2014, 9, e89880.	1.1	31
141	Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. <i>Lancet Oncology, The</i> , 2013, 14, 1233-1242.	5.1	215
142	Molecular Markers to Predict Response to Therapy. <i>Seminars in Oncology</i> , 2013, 40, 444-458.	0.8	18
143	Illness Uncertainty and Quality of Life of Patients with Small Renal Tumors Undergoing Watchful Waiting: A 2-year Prospective Study. <i>European Urology</i> , 2013, 63, 1122-1127.	0.9	88
144	Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 450-454.	0.6	7

#	ARTICLE	IF	CITATIONS
145	The Impact of Tyrosine Kinase Inhibitors on the Multimodality Treatment of Brain Metastases From Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 620-624.	0.6	49
146	Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2013, 19, 2460-2472.	3.2	72
147	Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. <i>BJU International</i> , 2013, 111, 997-1005.	1.3	22
148	Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features. <i>Chinese Journal of Cancer</i> , 2013, 32, 303-311.	4.9	19
149	Chemotherapy, Targeted Therapies, and Biological Therapies for Renal Cell Carcinoma. , 2013, , 713-725.		0
150	Agents That Stabilize Mutated von Hippelâ€Lindau (VHL) Protein: Results of a High-Throughput Screen to Identify Compounds That Modulate VHL Proteostasis. <i>Journal of Biomolecular Screening</i> , 2012, 17, 572-580.	2.6	23
151	Testicular Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 502-535.	2.3	71
152	Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 3961-3971.	3.2	138
153	A Phase 2 Trial of Sunitinib in Patients with Advanced Nonâ€clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2012, 62, 1013-1019.	0.9	139
154	Renal Tumors. , 2012, , 287-309.		0
155	An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. <i>Proteome Science</i> , 2012, 10, 56.	0.7	59
156	State of the Science: An Update on Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2012, 10, 859-880.	1.5	142
157	Pazopanib therapy for cerebellar hemangioblastomas in von Hippelâ€Lindau disease. <i>Targeted Oncology</i> , 2012, 7, 145-149.	1.7	34
158	Ten Years of Progress in Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 690-693.	2.3	10
159	Presurgical Therapy in Renal Cell Carcinoma. , 2012, , 241-247.		0
160	Regulation of SETD2, a histone methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 368-368.	0.8	1
161	Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma. <i>Journal of Urology</i> , 2011, 185, 439-444.	0.2	113
162	Clinical genomics of renal epithelial tumors. <i>Cancer Genetics</i> , 2011, 204, 285-297.	0.2	80

#	ARTICLE	IF	CITATIONS
163	Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma. <i>Current Clinical Pharmacology</i> , 2011, 6, 189-198.	0.2	12
164	Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma. <i>Current Clinical Pharmacology</i> , 2011, 6, 144-150.	0.2	13
165	Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. <i>BJU International</i> , 2011, 107, 741-747.	1.3	27
166	A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. <i>BJU International</i> , 2011, 108, 679-686.	1.3	54
167	Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2011, 59, 10-15.	0.9	98
168	Safety of Presurgical Targeted Therapy in the Setting of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2011, 60, 964-971.	0.9	89
169	Pilot Trial of Bone-Targeted Therapy Combining Zoledronate With Fluvastatin or Atorvastatin for Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2011, 9, 81-88.	0.9	18
170	Have Molecularly Targeted Therapies Improved Overall Survival in Renal Cell Carcinoma?. <i>Current Oncology Reports</i> , 2011, 13, 153-156.	1.8	1
171	Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. <i>Cancer</i> , 2011, 117, 4958-4965.	2.0	48
172	Axitinib in the treatment of metastatic renal cell carcinoma. <i>Future Oncology</i> , 2011, 7, 1247-1253.	1.1	28
173	Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. <i>Modern Pathology</i> , 2011, 24, 1470-1479.	2.9	101
174	Systemic therapy for sarcomatoid renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 913-920.	1.1	8
175	Durable Remission of Metastatic Renal Cell Carcinoma With Gemcitabine and Capecitabine After Failure of Targeted Therapy. <i>Journal of Clinical Oncology</i> , 2011, 29, e203-e205.	0.8	17
176	Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. <i>Annals of Oncology</i> , 2011, 22, 2661-2666.	0.6	96
177	Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2010, 116, 57-65.	2.0	105
178	Targeted therapy for locally advanced renal cell carcinoma. <i>Targeted Oncology</i> , 2010, 5, 113-118.	1.7	5
179	Prognostic and Predictive Factors in the Targeted Therapy Era: Filling in the Blanks. <i>Current Oncology Reports</i> , 2010, 12, 143-145.	1.8	0
180	Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials. <i>European Urology</i> , 2010, 58, 819-828.	0.9	89

#	ARTICLE	IF	CITATIONS
181	Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. <i>Cancer</i> , 2010, 116, 5219-5225.	2.0	121
182	Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. <i>Annals of Oncology</i> , 2010, 21, 1599-1606.	0.6	41
183	1661 DOES TARGETED THERAPY RESULT IN RELIABLE AND MEANINGFUL PRIMARY TUMOR DOWNSTAGING IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA?. <i>Journal of Urology</i> , 2010, 183, .	0.2	2
184	Percutaneous Biopsy of Primary Tumor in Metastatic Renal Cell Carcinoma to Predict High Risk Pathological Features: Comparison With Nephrectomy Assessment. <i>Journal of Urology</i> , 2010, 184, 1877-1881.	0.2	67
185	Long-term management of patients with metastatic renal cell carcinoma on targeted agents. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1883-1889.	1.1	9
186	Papillary Renal Cell Carcinoma: Radiologic-Pathologic Correlation and Spectrum of Disease. <i>Radiographics</i> , 2009, 29, 741-754.	1.4	123
187	Cytoplasmic Sequestration of p27 via AKT Phosphorylation in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 81-90.	3.2	54
188	Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4076-4081.	0.8	183
189	Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 386-391.	1.8	120
190	Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon. <i>Cancer</i> , 2009, 115, 1859-1866.	2.0	30
191	Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. <i>Cancer</i> , 2009, 115, 2346-2354.	2.0	25
192	Prognostic models. <i>Cancer</i> , 2009, 115, 2028-2030.	2.0	3
193	Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. <i>BJU International</i> , 2009, 104, 456-460.	1.3	53
194	Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma. <i>Urology</i> , 2009, 73, 337-341.	0.5	32
195	Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 20-23.	0.9	103
196	Kidney Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 618-630.	2.3	249
197	Testicular Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 672-693.	2.3	103
198	Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. <i>Current Oncology Reports</i> , 2008, 10, 253-258.	1.8	9

#	ARTICLE	IF	CITATIONS
199	Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2008, 113, 72-77.	2.0	40
200	Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. <i>British Journal of Cancer</i> , 2008, 98, 1336-1341.	2.9	61
201	Patterns of intervention for renal lesions in von Hippel-Lindau disease. <i>BJU International</i> , 2008, 102, 940-945.	1.3	32
202	A Phase II Trial of Gemcitabine Plus Capecitabine for Metastatic Renal Cell Cancer Previously Treated With Immunotherapy and Targeted Agents. <i>Journal of Urology</i> , 2008, 180, 867-872.	0.2	54
203	Surgical Morbidity Associated With Administration of Targeted Molecular Therapies Before Cytoreductive Nephrectomy or Resection of Locally Recurrent Renal Cell Carcinoma. <i>Journal of Urology</i> , 2008, 180, 94-98.	0.2	157
204	A Novel Von Hippel-Lindau Point Mutation Presents as Apparently Sporadic Pheochromocytoma. <i>Cancer Investigation</i> , 2008, 26, 642-646.	0.6	2
205	Inhibition of Mxi1 suppresses HIF-2 α -dependent renal cancer tumorigenesis. <i>Cancer Biology and Therapy</i> , 2008, 7, 1619-1627.	1.5	16
206	Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2008, 14, 315-319.	1.0	16
207	Presurgical therapy in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 73-78.	1.1	13
208	Cytoreductive Nephrectomy for T4NxM1 Renal Cell Carcinoma: The M.D. Anderson Cancer Center Experience. <i>Urology</i> , 2007, 69, 835-838.	0.5	23
209	Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. <i>Cancer</i> , 2006, 106, 2143-2147.	2.0	15
210	Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon- γ for metastatic renal cell carcinoma. <i>Cancer</i> , 2006, 107, 497-505.	2.0	14
211	Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon- γ -2b. <i>Cancer</i> , 2006, 107, 2254-2261.	2.0	38
212	Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. <i>Melanoma Research</i> , 2005, 15, 77-82.	0.6	108
213	Port-Site Metastasis: The Influence of Biology. <i>European Urology</i> , 2005, 47, 357-360.	0.9	21
214	Percutaneous Radiofrequency Ablation of Renal Tumors: Technique, Complications, and Outcomes. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, 679-688.	0.2	109
215	Lysophosphatidic acid production and action: Validated targets in cancer?. <i>Journal of Cellular Biochemistry</i> , 2004, 92, 1115-1140.	1.2	91
216	Melanoma of unknown primary: experience at the dana farber-partners cancer center and review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, P6.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Melanoma: what the primary care physician needs to know. Primary Care Update for Ob/Gyns, 2003, 10, 51-59.	0.1	0
218	Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood, 2003, 102, 3829-3836.	0.6	143
219	Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities. Oncologist, 2001, 6, 34-55.	1.9	478
220	Melanoma vaccination: state-of-the-art and experimental approaches. Expert Review of Anticancer Therapy, 2001, 1, 427-440.	1.1	1
221	Ras- and Raf-induced Down-modulation of Non-muscle Tropomyosin Are MEK-independent. Journal of Biological Chemistry, 1998, 273, 32182-32186.	1.6	34